A Retrospective Study of EGFR-TKIs,Gefitinib, Erlotinib and Osimertinib in NSCLC Patients Treatment

RecruitingOBSERVATIONAL

Enrollment

1,000

Participants

Timeline

Start Date

September 30, 2012

Primary Completion Date

October 31, 2025

Study Completion Date

December 31, 2026

Conditions

Non-small Cell Lung Cancer (NSCLC)EGFR-TKI Resistant MutationEGFR-TKI Sensitizing MutationGermline MutationsSomatic Mutation

Trial Locations (1)

RECRUITING

Cancer Center, Sun Yat-sen University, Guangzhou

All Listed Sponsors

lead

Sun Yat-sen University

OTHER